These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 18008070

  • 1. Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.
    Beumer JH, Eiseman JL, Parise RA, Florian JA, Joseph E, D'Argenio DZ, Parker RS, Kay B, Covey JM, Egorin MJ.
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):457-64. PubMed ID: 18008070
    [Abstract] [Full Text] [Related]

  • 2. Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.
    Beumer JH, Eiseman JL, Gilbert JA, Holleran JL, Yellow-Duke AE, Clausen DM, D'Argenio DZ, Ames MM, Hershberger PA, Parise RA, Bai L, Covey JM, Egorin MJ.
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):421-30. PubMed ID: 20443002
    [Abstract] [Full Text] [Related]

  • 3. Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans.
    Holleran JL, Beumer JH, McCormick DL, Johnson WD, Newman EM, Doroshow JH, Kummar S, Covey JM, Davis M, Eiseman JL.
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):803-11. PubMed ID: 26321472
    [Abstract] [Full Text] [Related]

  • 4. Quantitative determination of the cytidine deaminase inhibitor tetrahydrouridine (THU) in mouse plasma by liquid chromatography/electrospray ionization tandem mass spectrometry.
    Parise RA, Egorin MJ, Eiseman JL, Joseph E, Covey JM, Beumer JH.
    Rapid Commun Mass Spectrom; 2007 Oct; 21(13):1991-7. PubMed ID: 17526067
    [Abstract] [Full Text] [Related]

  • 5. Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine.
    Beumer JH, Eiseman JL, Parise RA, Joseph E, Covey JM, Egorin MJ.
    Clin Cancer Res; 2008 Jun 01; 14(11):3529-35. PubMed ID: 18519786
    [Abstract] [Full Text] [Related]

  • 6. Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man.
    Kreis W, Woodcock TM, Gordon CS, Krakoff IH.
    Cancer Treat Rep; 1977 Oct 01; 61(7):1347-53. PubMed ID: 589600
    [Abstract] [Full Text] [Related]

  • 7. Epimer interconversion, isomerization, and hydrolysis of tetrahydrouridine: implications for cytidine deaminase inhibition.
    Xiang TX, Niemi R, Bummer P, Anderson BD.
    J Pharm Sci; 2003 Oct 01; 92(10):2027-39. PubMed ID: 14502542
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice.
    Beumer JH, Eiseman JL, Parise RA, Joseph E, Holleran JL, Covey JM, Egorin MJ.
    Clin Cancer Res; 2006 Dec 15; 12(24):7483-91. PubMed ID: 17138702
    [Abstract] [Full Text] [Related]

  • 9. Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels.
    Funamizu N, Lacy CR, Fujita K, Furukawa K, Misawa T, Yanaga K, Manome Y.
    PLoS One; 2012 Dec 15; 7(5):e37424. PubMed ID: 22616006
    [Abstract] [Full Text] [Related]

  • 10. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
    Avramis VI, Powell W.
    Cancer Invest; 1987 Dec 15; 5(4):293-9. PubMed ID: 3664332
    [Abstract] [Full Text] [Related]

  • 11. Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites.
    Besnard T, Renée N, Etienne-Grimaldi MC, François E, Milano G.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jul 01; 870(1):117-20. PubMed ID: 18562256
    [Abstract] [Full Text] [Related]

  • 12. Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.
    Lavelle D, Vaitkus K, Ling Y, Ruiz MA, Mahfouz R, Ng KP, Negrotto S, Smith N, Terse P, Engelke KJ, Covey J, Chan KK, Desimone J, Saunthararajah Y.
    Blood; 2012 Feb 02; 119(5):1240-7. PubMed ID: 22160381
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase.
    Ferraris D, Duvall B, Delahanty G, Mistry B, Alt J, Rojas C, Rowbottom C, Sanders K, Schuck E, Huang KC, Redkar S, Slusher BB, Tsukamoto T.
    J Med Chem; 2014 Mar 27; 57(6):2582-8. PubMed ID: 24520856
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine.
    Lau H, Woost PG, Friedrich U, Clausen WHO, Jacobberger JW, Saunthararajah Y.
    Eur J Haematol; 2023 Sep 27; 111(3):345-355. PubMed ID: 37417197
    [Abstract] [Full Text] [Related]

  • 15. Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine.
    Riccardi R, Chabner B, Glaubiger DL, Wood J, Poplack DG.
    Cancer Res; 1982 May 27; 42(5):1736-9. PubMed ID: 6896013
    [Abstract] [Full Text] [Related]

  • 16. Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells.
    Eliopoulos N, Cournoyer D, Momparler RL.
    Cancer Chemother Pharmacol; 1998 May 27; 42(5):373-8. PubMed ID: 9771951
    [Abstract] [Full Text] [Related]

  • 17. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.
    Kreis W, Hession C, Soricelli A, Scully K.
    Cancer Treat Rep; 1977 Oct 27; 61(7):1355-64. PubMed ID: 589601
    [Abstract] [Full Text] [Related]

  • 18. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).
    Beumer JH, Parise RA, Newman EM, Doroshow JH, Synold TW, Lenz HJ, Egorin MJ.
    Cancer Chemother Pharmacol; 2008 Jul 27; 62(2):363-8. PubMed ID: 17899082
    [Abstract] [Full Text] [Related]

  • 19. Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice.
    Terse P, Engelke K, Chan K, Ling Y, Sharpnack D, Saunthararajah Y, Covey JM.
    Int J Toxicol; 2014 Jul 27; 33(2):75-85. PubMed ID: 24639139
    [Abstract] [Full Text] [Related]

  • 20. Stability of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in combination.
    Guo D, Myrdal PB, Karlage KL, O'Connell SP, Wissinger TJ, Tabibi SE, Yalkowsky SH.
    AAPS PharmSciTech; 2010 Mar 27; 11(1):247-52. PubMed ID: 20151336
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.